Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
NOTV 
Inotiv Inc (NOTV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/12/2025: NOTV (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.83
1 Year Target Price $4.83
| 2 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -2.62% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 26.26M USD | Price to earnings Ratio - | 1Y Target Price 4.83 |
Price to earnings Ratio - | 1Y Target Price 4.83 | ||
Volume (30-day avg) 3 | Beta 4.35 | 52 Weeks Range 0.66 - 6.48 | Updated Date 12/13/2025 |
52 Weeks Range 0.66 - 6.48 | Updated Date 12/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.11 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-12-03 | When - | Estimate -0.33 | Actual -0.25 |
Profitability
Profit Margin -13.38% | Operating Margin (TTM) -10.32% |
Management Effectiveness
Return on Assets (TTM) -2.98% | Return on Equity (TTM) -44.78% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 463810453 | Price to Sales(TTM) 0.05 |
Enterprise Value 463810453 | Price to Sales(TTM) 0.05 | ||
Enterprise Value to Revenue 0.9 | Enterprise Value to EBITDA 18.74 | Shares Outstanding 34367251 | Shares Floating 31272136 |
Shares Outstanding 34367251 | Shares Floating 31272136 | ||
Percent Insiders 11.31 | Percent Institutions 23.97 |
About Inotiv Inc
Exchange NASDAQ | Headquaters West Lafayette, IN, United States | ||
IPO Launch date 1997-11-25 | President, CEO & Director Mr. Robert W. Leasure Jr. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 1945 | Website https://www.inotiv.com |
Full time employees 1945 | Website https://www.inotiv.com | ||
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. The company operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.